Allos Therapeutics, Inc.
Allos Therapeutics, Inc., officials detail recent developments
Published in Lab Law Weekly, August 3rd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Allos Therapeutics, Inc.
Report 1: Allos Therapeutics, Inc. (NASDAQ:ALTH) announced the initiation of patient enrollment in a Phase I/IIa open-label, multi-center study of sequential PDX (pralatrexate) and gemcitabine with vitamin B12 and folic acid supplementation in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's disease.
"We are excited to advance the development of this promising treatment regimen," said Pablo J. Cagnoni, M.D., Chief...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2007-08-03)
More Articles from Lab Law Weekly
- Aarp
Status: - Boston Scientific Corporation
Boston Scientific Announces Agreement to Settle Product Lawsuits - Cancer
Edward Unveils Details of Plans for Hospital, Cancer Center in Plainfield; New state law positively impacts application - Cancer Vaccines
Novartis delivers strong performance in first half of 2007 (H1 - Report) - Clinical Data, Inc.
Clinical Data Prices 3,000,000 Share Common Stock Offering - Clinical Trial Research
ArQule Announces Exercise of over-Allotment Option - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
